Earnings Call · Q4 FY2023·2024-03-04

Q4 23EPS -31.11%·Rev n/aQ3 23EPS 0.00%·Rev n/aQ2 23EPS -7.41%·Rev n/aQ1 23EPS +3.92%·Rev n/a⚠ consensus missing

Tvardi Therapeutics, Inc. TVRD

Matt Murphy

Chris Posner — Chief Executive Officer

Ryan Maynard — Chief Financial Officer

−9.0%1d on move date−8.0% vs SPY3d+5.0%5d−5.0%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more TVRD calls or request research access.

More TVRD calls Browse calls Request research access